MINNNEAPOLIS (April 18, 2023) – Sofia Fund, the angel investment firm focused exclusively on women-led companies, announces that its managing partner, long-term investor and entrepreneur Joy Lindsay, is the recipient of the 2023 Entrepreneur of the Year Award, presented by the University of Minnesota.…
Sofia Fund News
Cathy Connett named to Notable Leaders in Private Equity, Investment Banking and Venture Capital List
Twin Cities Business magazine has named Sofia Fund CEO, Cathy Connett to its 2021 list of Notable Leaders in Private Equity, Investment Banking and Venture Capital List in their Dec/Jan issue.…
Sofia Fund Partner Joy Lindsay Recognized for Lifetime Achievement as Technology Investor
MINNNEAPOLIS (Nov. 17, 2021) – Sofia Fund, the angel investment firm focused exclusively on women-led companies, announces that its partner, long-term investor Joy Lindsay, has received the Lifetime Achievement Award for an outstanding career in technology from the Minnesota Technology Association (MnTech).…
Oculogica Receives Department of Defense Grant to Develop Wearable Concussion Diagnostic with Pre-eminent Partners
Sofia Fund portfolio company Oculogica receives $2M U.S. Army grant to develop wearable version of its technology
Keller Army Hospital at West Point, Children’s Hospital of Philadelphia, University of Wisconsin-Green Bay and AdHawk Microsystems will work with Oculogica to develop the wearable diagnostic.…
Kenzen Announces Device Rental Program for Summer 2021
Rapid deployment of life-saving smart PPE critical for hottest summer on record ahead
NEW YORK CITY (May 12, 2021) – In anticipation of what the U.S. National Weather Service and U.K. Met Office predict to be the hottest summer on record, Kenzen, makers of smart PPE that monitors the heat health of workers in hot and humid conditions, announced a new rental program for its wearable devices.…
Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease
Mutation Validates Cognition Approach to Oligomer Displacement
Pittsburgh, October 19, 2020 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that a peer-reviewed manuscript, entitled, “Icelandic Mutant Human Amyloid-β 1-42 Peptide Forms Fewer Oligomers with Lower Binding Affinity than Wild-Type Peptide,” has been published online in the Journal of Neurochemistry (doi:10.1111/jnc.15212).…
Joylux Founder, Colette Courtion, Named to Inc.’s Female Founders 100 list
Seattle, WA October 13, 2020 — Inc. today announced its third annual Female Founders 100 list, honoring an influential, ambitious, and diverse group of 100 women who are building America’s most inspiring and innovative businesses. Colette Courtion, the founder of Joylux, a platform of life-changing solutions for menopausal women, is proud to be acknowledged in this prestigious list of female founders.…
Joylux leading the charge for intimate care with femtech, Beauty Insider reports
Colette Courtion shares her vision for the future of solving women’s intimate issues, now with renown dermatologist and successful entrepreneur Dr. Kathy Fields on the board. Joylux is a femtech company innovating intimate care products for use at all stages of women’s health – from motherhood to menopause. …
Legendary Beauty Innovator Dr. Kathy Fields Places Big Bet on Femtech Pioneer Joylux
Seattle, July 16, 2020. Joylux, a leader in high-tech vaginal health and wellness devices and products targeting menopausal women, announced that Dr. Kathy Fields—the cofounder of leading skincare brand Rodan + Field and co-creator of Proactiv—is joining their board of directors.…
Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study
Pittsburgh, August 27, 2020 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has dosed the first patient in the SEQUEL (Study of EEG QUantification with ELayta) Study of CT1812 (Elayta™) in adults with mild-to-moderate Alzheimer’s disease.…